Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2022 09:00 ET | Source: Enterin Inc.

Enterin Meets Study Endpoints for the Phase 2b (KARMET) Study Involving Patients With Parkinson's Disease

PHILADELPHIA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 25, 2022 09:00 ET | Source: Enterin Inc.

Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson's Disease

PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 11, 2022 15:00 ET | Source: Enterin Inc.

Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function

PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 10, 2022 09:00 ET | Source: Enterin Inc.

Enterin Announces Appointment of Dr. Patrik Brundin to Its Scientific Advisory Board

PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
November 19, 2021 09:00 ET | Source: Enterin Inc.

Enterin Announces Publication of Exciting Discoveries About the Enterin Nervous System

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held Philadelphia-based clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
September 13, 2021 09:00 ET | Source: Enterin Inc.

Enterin Announces Appointment of Dr. Roger Mills to Its Board of Directors

PHILADELPHIA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enterin, Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...